Leadership Team & Board of Directors | Amicus Therapeutics

Leadership

A passionate team with a purpose

We are driven toward invention and healing. Committed to delivering meaningful benefits to the rare and orphan disease community, our dedicated leadership team is the driving force behind our developments. They are constantly inspired by others in the rare disease community, and continually aspire to reach new heights.

John F. Crowley

Chairman of the Board, Chief Executive Officer

John F. Crowley is our Chairman and CEO. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder, President and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children’s lives). In 2001, Novazyme was acquired by Genzyme Corporation and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.

John and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand, “The Cure: How a Father Raised $100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children.” The major motion picture, Extraordinary Measures, starring Brendan Fraser and Harrison Ford, is inspired by the Crowley family journey. John is the author of a personal memoir: Chasing Miracles: The Crowley Family Journey of Strength, Hope, and Joy.

John is also a commissioned officer in the U.S. Navy Reserve, assigned to the United States Special Operations Command and is a veteran of the global war on terrorism, with service in Afghanistan. He graduated with a B.S. in Foreign Service from Georgetown University, and earned a J.D. from the University of Notre Dame Law School and an M.B.A. from Harvard. The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame. He is also a member of the University Council on Science & Technology at Notre Dame. He is the National Chairman of the Make A Wish Foundation of America and is a founding Board member of the Global Genes Project. John is a Henry Crown Fellow at the Aspen Institute.

Bradley L. Campbell

President and Chief Operating Officer

Bradley L. Campbell is the President and Chief Operating Officer of Amicus (NASDAQ: FOLD) and brings over 15 years of experience in the Orphan Drug industry. Mr. Campbell joined Amicus in 2006 and leads the global commercial organization responsible for the strategy, design and execution of the launch of Galafold™. He also oversees the Technical Operations, Market Access, and Program Management functions.

Prior to Amicus, Mr. Campbell spent time in various commercial and business development roles at Genzyme and Bristol-Myers Squibb and as a strategy consultant for Marakon Associates.

Mr. Campbell is active with various Boards and philanthropic organizations. He currently serves as a member of the Board of Directors of Progenics Pharmaceuticals (NASDAQ: PGNX), a pharmaceutical company focused developing medicines to identify, target and treat cancer. He is also a member of the BioNJ Board and of the Corporate Advisory Board for the National Tay-Sachs and Allied Diseases Association. Bradley received a B.A. in Public Policy from Duke University and an M.B.A. from Harvard Business School.

William D. "Chip" Baird, III

Chief Financial Officer

William D. “Chip” Baird joined Amicus Therapeutics in April 2012 as Chief Financial Officer. He brings experience in finance and strategic planning. Prior to Amicus Mr. Baird held roles of increasing responsibility for over 10 years at PTC Therapeutics, Inc. As Chief Financial Officer of PTC from April 2005 to April 2012, he was responsible for all areas of finance, investor and public relations, human resources, facilities and project management. During his tenure at PTC, he was instrumental in raising over $500 million through a combination of venture capital, non-dilutive grant funding, collaborations with industry-leading pharmaceutical and biotech companies, and debt financings. Previously, Mr. Baird worked at L.E.K. Consulting, a strategy consulting firm, from 1999 to 2002 and at First Union National Bank as a corporate underwriter from 1994 to 1997.

Mr. Baird currently serves as a Director of Axcella Health. Mr. Baird received a B.S. from Georgetown University’s Edmund A. Walsh School of Foreign Service and an M.B.A. in finance from The Wharton School of the University of Pennsylvania.

Daphne Quimi

Senior Vice President, Finance and Administration

Daphne Quimi joined Amicus in October 2005 and currently serves as Senior Vice President, Finance and Corporate Controller. She brings experience in public accounting and financial reporting. Prior to Amicus, Ms. Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb. She also held roles of increasing responsibility in the finance department at Johnson & Johnson. Ms. Quimi received a B.S. in Accountancy from Monmouth University and an M.B.A from the Stern School of Business of New York University. She is a certified public accountant in New Jersey and a member of the American Institute of Certified Public Accountants and the Institute of Management Accountants.

Ellen S. Rosenberg

General Counsel and Corporate Secretary

Ellen S. Rosenberg joined Amicus Therapeutics in February of 2016 as General Counsel and Corporate Secretary. She brings legal experience in the biopharmaceutical and medical device industry including mergers and acquisitions, product launches, risk management, and compliance matters. Prior to joining Amicus, she served as Senior Vice President, Associate General Counsel of Shire Pharmaceuticals. Prior to Shire, Ms. Rosenberg was Associate General Counsel for the Metabolic Endocrinology division at EMD Serono Inc., the U.S. affiliate of Merck KGaA.

Ms. Rosenberg received a B.A. from the University of Connecticut and a J.D. from the University of Pennsylvania Law School.

Jay A. Barth M.D.

Chief Medical Officer

Jay A. Barth joined Amicus Therapeutics in March 2014 as Chief Medical Officer. Dr. Barth brings experience in drug development, clinical research and medical affairs. Prior joining Amicus, Dr. Barth held roles of increasing responsibility at PTC Therapeutics, Inc. from 2009 to 2014. He most recently served as PTC’s Senior Vice President, Clinical Development. In this role he led the clinical team and oversaw all global clinical development programs, focusing on rare diseases including Duchenne Muscular Dystrophy and Cystic Fibrosis. Previously Dr. Barth served as Executive Director of Clinical Research at Merck; as Vice President, Clinical Research and Medical Affairs at Altana Pharma US, Inc; and as Senior Director, Global Head of Gastroenterology Clinical Research at Eisai Medical Research Inc.

Dr. Barth received a B.A. from Columbia University and an M.D. from the University of Pennsylvania School of Medicine. He is a member of the American Gastroenterological Association, the American College of Gastroenterology, and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. He is also the author of numerous publications in the fields of medicine and clinical research.

Jeffrey P. Castelli Ph.D.

Chief Portfolio Officer

Jeffrey P. Castelli joined Amicus in July 2005 and currently serves as Chief Portfolio Officer. He brings over 15 years of experience in the Biotech and Orphan Drug industry, focused on program management, portfolio planning, business operations, and alliance management. After joining Amicus in 2005, he subsequently took on roles of increasing responsibility within business operations. In his current capacity, Dr. Castelli provides strategic guidance and oversight across all research and development activities, including direct responsibility for the Program Management, Portfolio Planning and Statistical Science functions. Prior to joining Amicus, Dr. Castelli was a healthcare strategy consultant at Health Advances LLC and also previously worked in business development at Neose Pharmaceuticals Inc.

Dr. Castelli received a B.S. from West Chester University and a Ph.D. from the University of Pennsylvania. He is also an author on numerous publications and several patents in the field of rare disease drug development.

John F. Crowley

Chairman of the Board, Chief Executive Officer

John F. Crowley is our Chairman and CEO. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder, President and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children’s lives). In 2001, Novazyme was acquired by Genzyme Corporation and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.

John and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand, “The Cure: How a Father Raised $100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children.” The major motion picture, Extraordinary Measures, starring Brendan Fraser and Harrison Ford, is inspired by the Crowley family journey. John is the author of a personal memoir: Chasing Miracles: The Crowley Family Journey of Strength, Hope, and Joy.

John is also a commissioned officer in the U.S. Navy Reserve, assigned to the United States Special Operations Command and is a veteran of the global war on terrorism, with service in Afghanistan. He graduated with a B.S. in Foreign Service from Georgetown University, and earned a J.D. from the University of Notre Dame Law School and an M.B.A. from Harvard. The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame. He is also a member of the University Council on Science & Technology at Notre Dame. He is the National Chairman of the Make A Wish Foundation of America and is a founding Board member of the Global Genes Project. John is a Henry Crown Fellow at the Aspen Institute.

Donald J. Hayden , Jr.

Lead Independent Director

Donald J. Hayden, Jr. has served as a member of our Board since March 2006 and as Lead Independent Director since February 2010. Mr. Hayden served as Chairman from March 2006 until February 2010 and from September 2006 until March 2007 as Interim President and Chief Executive Officer. From 1981 to 2006, he held several executive positions with Bristol-Myers Squibb Company, most recently serving as Executive Vice President and President, Americas. Mr. Hayden is Senior Advisor to Prospect Venture Partners, a life sciences venture capital firm, since 2006 and is a member of the Board of Directors of Insmed Incorporated, Vitae Pharmaceuticals, Regenexbio and Otsuka (Tokyo).

Mr. Hayden holds a B.A. from Harvard University and an M.B.A. from Indiana University.

Glenn P. Sblendorio

President & Chief Executive Officer, Ophthotech

Glenn P. Sblendorio has served as a member of our Board since June 2006. Since April 1, 2016, Mr. Sblendorio has served as Executive Vice President, Chief Operating Officer and Chief Financial Officer of Ophthotech Corporation and was a member of the Board of Directors of Ophthotech until March 31, 2016. Prior to Opthotech, Mr. Sblendorio was President and Chief Financial Officer of The Medicines Company from March, 2006 through March, 2016 and was a member of the Board of Directors of the Medicines Company from July 2011 through December 31, 2015. Before joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. Mr. Sblendorio also serves as a member of the Boards of Directors of Intercept Pharmaceuticals and NuLens Ltd., a privately held company.

Mr. Sblendorio received his B.B.A. from Pace University and his M.B.A. from Fairleigh Dickinson University.

Margaret G. Mcglynn R.Ph.

Margaret G. McGlynn has served as a member of our Board since October 2009. Ms. McGlynn has served as CEO and President of The International AIDS Vaccine Initiative since July 2011. She previously served as President, Vaccines and Infectious Diseases of Merck & Co., Inc. from 2005 until her retirement in 2009. Ms. McGlynn joined Merck in 1983, and served in a variety of marketing, sales and managed care roles. Currently, Ms. McGlynn serves as a member of the Boards of Directors of Air Products and Chemicals, Inc. and Vertex Pharmaceuticals, Inc. She is also a member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences.

Ms. McGlynn holds a B.S. in Pharmacy and a MBA in Marketing from the State University of New York at Buffalo.

Michael G. Raab

Chief Executive Officer and Chairman, Ardelyx

Michael G. Raab has served as a member of our Board of Directors since 2004. Mr. Raab has served as President and Chief Executive Officer of Ardelyx, Inc. since March 2009. Mr. Raab previously served as a partner of New Enterprise Associates from June 2002 until December 2008. From 1999 to 2002, he was a Senior Vice President, Therapeutics and General Manager, Renagel® at Genzyme Corporation. Mr. Raab currently serves as a member of the Board of Directors of Ardelyx, Inc.

Mr. Raab holds a B.A. from DePauw University.

Robert Essner

Senior Advisor, The Carlyle Group

Robert Essner has served as a member of the Board since June 2012. Mr. Essner is Senior Advisor to the global healthcare group at The Carlyle Group, a global private equity firm. Mr. Essner retired as Chairman and Chief Executive Officer of Wyeth, now part of Pfizer, in 2008. During his 32-year career in the pharmaceutical industry, he held several prominent leadership positions, including Chairman of the Pharmaceutical Research and Manufacturers Association. Prior to Wyeth, Mr. Essner spent more than a decade in various management positions at Sandoz Pharmaceuticals Corporation and as President of Sandoz Consumer Healthcare Group. Mr. Essner is currently a Director at MassMutual Financial Group (Chairman). Mr. Essner is also an Executive-in-Residence and Adjunct Professor at Columbia Business School, where he teaches courses in healthcare management.

He received a Bachelor’s degree from Miami University and a Master’s degree from the University of Chicago.

Ted W. Love M.D.

Board of Directors, Global Blood Therapeutics

Ted W. Love, M.D., has served as a member of the Board since June 2012. From February 2010 to August 2012, Dr. Love served as Executive Vice President and Head of Research and Development of Onyx Pharmaceuticals. From 2001 to 2009, Dr. Love was the President, Chief Executive Officer and Chairman of the Board of Directors of Nuvelo. Before joining Nuvelo in 2001, he served as Senior Vice President of Development at Theravance, Inc. Prior to that, Dr. Love spent six years at Genentech, Inc. in a number of senior management positions in Medical Affairs and Product Development. As Vice President of Product Development and Regulatory Affairs at Genentech, Dr. Love oversaw all drugs in development including Herceptin, Rituxan, and TNKase. He also served as chairman of Genentech’s Product Development Committee. In addition to Amicus, Dr. Love currently serves on the Board of Directors of Oncothyreon and Global Blood (CEO).

Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School.

Craig A. Wheeler

President and Chief Executive Officer, Momenta Pharmaceuticals

Craig A. Wheeler has served as a member of our Board since June 2016. He is currently President and Chief Executive Officer of Momenta Pharmaceuticals, Inc., where he also serves on the board of directors. Mr. Wheeler led Momenta through the launch of its first complex drug products, including the first generic versions of LOVENOX® and once-daily COPAXONE®. Prior to Momenta, Craig worked at Chiron Corporation as President, Chiron BioPharmaceuticals (now Novartis Vaccines ↦ Diagnostics). Prior to joining Chiron, Craig was a senior member of The Boston Consulting Group’s health care practice. Mr. Wheeler also worked for Merck’s MSDRL research unit, where he served as a senior engineer in process development and at Hybritech as a financial analyst. Mr. Wheeler previously served for nine years as the Chairman of the Board of Avanir Pharmaceuticals where he helped oversee the transition of the company from a research-based platform to a fully integrated CNS pharmaceutical company until 2015 when it was acquired by Otsuka Pharmaceuticals for $3.5 billion. He also served as GPhA’s Chairman of the Board of Directors from 2014 to February 2016.

He holds a BS and an MS degree in chemical engineering from Cornell University, and an MBA from the Wharton School of the University of Pennsylvania.

Bradley L. Campbell

President and Chief Operating Officer

Bradley L. Campbell is the President and Chief Operating Officer of Amicus (NASDAQ: FOLD) and brings over 15 years of experience in the Orphan Drug industry. Mr. Campbell joined Amicus in 2006 and leads the global commercial organization responsible for the strategy, design and execution of the launch of Galafold™. He also oversees the Technical Operations, Market Access, and Program Management functions.

Prior to Amicus, Mr. Campbell spent time in various commercial and business development roles at Genzyme and Bristol-Myers Squibb and as a strategy consultant for Marakon Associates.

Mr. Campbell is active with various Boards and philanthropic organizations. He currently serves as a member of the Board of Directors of Progenics Pharmaceuticals (NASDAQ: PGNX), a pharmaceutical company focused developing medicines to identify, target and treat cancer. He is also a member of the BioNJ Board and of the Corporate Advisory Board for the National Tay-Sachs and Allied Diseases Association. Bradley received a B.A. in Public Policy from Duke University and an M.B.A. from Harvard Business School.

Lynn D. Bleil

Lynn D. Bleil has served as a member of our Board since 2018. Ms. Bleil brings more than 25 years of experience in the healthcare sector, advising CEOs and Boards of leading healthcare companies on their most critical strategic, organizational and operational issues as a Senior Partner of McKinsey & Company. She has broad expertise in healthcare strategy, business development, go-to-market strategies, reimbursement and policy. Before retiring at the end of 2013, she led McKinsey & Company’s West Coast Healthcare Practice, and was a core leader of McKinsey’s worldwide Healthcare Practice.

Currently, Ms. Bleil serves on two public company healthcare Boards, including Sonova Holding AG and Stericycle, Inc. Previously, she served on the boards of DST Systems, Inc., and Auspex Pharmaceuticals until their sale to SS&C and Teva, respectively. She also serves on the Governing Board of Intermountain’s Park City Hospital. Ms. Bleil holds a bachelor’s degree in chemical engineering from Princeton University, magna cum laude, and a master’s degree in business administration from the Stanford Graduate School of Business, where she was an Arjay Miller Scholar.